These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35868851)

  • 21. [Bone and Calcium Research Update 2015. Novel treatment for FGF23-related hypophosphatemic diseases].
    Fukumoto S
    Clin Calcium; 2015 Jan; 25(1):37-44. PubMed ID: 25530521
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor Suppressor Activity of Klotho in Breast Cancer Is Revealed by Structure-Function Analysis.
    Ligumsky H; Rubinek T; Merenbakh-Lamin K; Yeheskel A; Sertchook R; Shahmoon S; Aviel-Ronen S; Wolf I
    Mol Cancer Res; 2015 Oct; 13(10):1398-407. PubMed ID: 26113466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.
    Wöhrle S; Henninger C; Bonny O; Thuery A; Beluch N; Hynes NE; Guagnano V; Sellers WR; Hofmann F; Kneissel M; Graus Porta D
    J Bone Miner Res; 2013 Apr; 28(4):899-911. PubMed ID: 23129509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanism of the Fibroblast Growth Factor 23/α-Klotho Axis in Peripheral Blood Mononuclear Cell Inflammation in Alzheimer's Disease.
    Li B; Zhou M; Peng J; Yang Q; Chu J; Li R; Jiang Y
    Immunol Invest; 2022 Jul; 51(5):1471-1484. PubMed ID: 34503373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conformational landscape of soluble α-klotho revealed by cryogenic electron microscopy.
    Schnicker NJ; Xu Z; Amir M; Gakhar L; Huang CL
    bioRxiv; 2024 Mar; ():. PubMed ID: 38496408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of phosphate transport by fibroblast growth factor 23 (FGF23): implications for disorders of phosphate metabolism.
    Gattineni J; Baum M
    Pediatr Nephrol; 2010 Apr; 25(4):591-601. PubMed ID: 19669798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Rickets/Osteomalacia. Anti-FGF23 antibody therapy in patients with FGF23-related hypophosphatemic rickets and osteomalacia.].
    Kinoshita Y
    Clin Calcium; 2018; 28(10):1373-1379. PubMed ID: 30269120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGF23 contains two distinct high-affinity binding sites enabling bivalent interactions with α-Klotho.
    Suzuki Y; Kuzina E; An SJ; Tome F; Mohanty J; Li W; Lee S; Liu Y; Lax I; Schlessinger J
    Proc Natl Acad Sci U S A; 2020 Dec; 117(50):31800-31807. PubMed ID: 33257569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.
    Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
    BMC Nephrol; 2021 Nov; 22(1):374. PubMed ID: 34758731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The anti-aging factor Klotho protects against acquired long QT syndrome induced by uremia and promoted by fibroblast growth factor 23.
    Navarro-García JA; Salguero-Bodes R; González-Lafuente L; Martín-Nunes L; Rodríguez-Sánchez E; Bada-Bosch T; Hernández E; Mérida-Herrero E; Praga M; Solís J; Arribas F; Bueno H; Kuro-O M; Fernández-Velasco M; Ruilope LM; Delgado C; Ruiz-Hurtado G
    BMC Med; 2022 Jan; 20(1):14. PubMed ID: 35042527
    [TBL] [Abstract][Full Text] [Related]  

  • 31. α-Klotho's effects on mineral homeostasis are fibroblast growth factor-23 dependent.
    Erben RG
    Curr Opin Nephrol Hypertens; 2018 Jul; 27(4):229-235. PubMed ID: 29851418
    [TBL] [Abstract][Full Text] [Related]  

  • 32. α-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling.
    Chen G; Liu Y; Goetz R; Fu L; Jayaraman S; Hu MC; Moe OW; Liang G; Li X; Mohammadi M
    Nature; 2018 Jan; 553(7689):461-466. PubMed ID: 29342138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble klotho regulates TRPC6 calcium signaling
    Wright JD; An SW; Xie J; Lim C; Huang CL
    FASEB J; 2019 Aug; 33(8):9182-9193. PubMed ID: 31063704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prediction of the structural interface between fibroblast growth factor23 and Burosumab using alanine scanning and molecular docking.
    Kanhasut K; Tharakaraman K; Ruchirawat M; Satayavivad J; Fuangthong M; Sasisekharan R
    Sci Rep; 2022 Aug; 12(1):14754. PubMed ID: 36042241
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear fibroblast growth factor 2 (FGF2) isoforms inhibit bone marrow stromal cell mineralization through FGF23/FGFR/MAPK in vitro.
    Xiao L; Esliger A; Hurley MM
    J Bone Miner Res; 2013 Jan; 28(1):35-45. PubMed ID: 22836867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGF23 and Hypophosphatemic Rickets/Osteomalacia.
    Takashi Y; Kawanami D; Fukumoto S
    Curr Osteoporos Rep; 2021 Dec; 19(6):669-675. PubMed ID: 34755323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGF23 and Bone and Mineral Metabolism.
    Fukumoto S
    Handb Exp Pharmacol; 2020; 262():281-308. PubMed ID: 31792685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-fibroblast growth factor 23 antibody therapy.
    Fukumoto S
    Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):346-51. PubMed ID: 24848934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic Effects of FGF23 c-tail Fc in a Murine Preclinical Model of X-Linked Hypophosphatemia Via the Selective Modulation of Phosphate Reabsorption.
    Johnson K; Levine K; Sergi J; Chamoun J; Roach R; Vekich J; Favis M; Horn M; Cao X; Miller B; Snyder W; Aivazian D; Reagan W; Berryman E; Colangelo J; Markiewicz V; Bagi CM; Brown TP; Coyle A; Mohammadi M; Magram J
    J Bone Miner Res; 2017 Oct; 32(10):2062-2073. PubMed ID: 28600887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FGF23-Klotho signaling axis in the kidney.
    Erben RG; Andrukhova O
    Bone; 2017 Jul; 100():62-68. PubMed ID: 27622885
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.